VacuVolt
Class II · 510(k)
The therapy device is being developed with an anticipated Class II 510(k) regulatory pathway. The company is in the pre-submission planning phase and has not obtained clearance.
Regulatory Strategy
Two Products. Two Anticipated Pathways.
The Marrian platform is being developed against two distinct regulatory tracks aligned with the two products. Both are anticipated pathways. No clearance has been obtained.
Wound Intelligence
Software-as-a-Medical-Device (SaMD)
The predictive software is being developed under the Software-as-a-Medical-Device framework. Validation, documentation, and human-in-the-loop review structures are being defined in parallel with model development.
Language and Compliance
What We Do and Do Not Claim
Marrian Medical Technologies is confident about the technology and the clinical problem it addresses. The company is careful about performance.
The therapy system is designed to accelerate wound closure; efficacy is under preclinical investigation. No performance figures are published on this site. FDA rules prohibit promoting an uncleared device, and Marrian follows those rules.
Nothing on this website should be interpreted as a representation of regulatory clearance, regulatory approval, commercial availability, clinical validation, or demonstrated safety or effectiveness.
Regulatory or Development Inquiry
For regulatory consultants, quality-system partners, and clinical collaborators who want to discuss the anticipated pathway in more detail.